Arobella Medical - Sound Touch for Wound Care™

Qoustic Wound Therapy System®

Health Canada issues Medical Device Licence to Arobella Medical, LLC

Minneapolis, Minn.(June 25, 2016) - In accordance with Health Canada Medical Devices Regulations, Section 36, Arobella Medical, LLC issued Medical Device Licence (Class 2 MDL LN97205) for the Qoustic Wound Therapy System™ platform, its variants and accessories.

This licence represents another major milestone for Arobella Medical’s passionate pursuit to advance the standard of care when it comes to treating and healing wounds.

Eliaz Babaev, CEO and President of Arobella Medical, LLC, “Currently in negotiations with several distributors, we are trying to bring this technology all across Canada and all the various provinces."

He added, "We are glad we can finally bring this improved standard of care to current wound care practices and facilities and offer another tool to improve the quality of life for patients with a wide variety of chronic and other types of troublesome wounds.”

The Qoustic Wound Therapy System™, Model AR1000 Series and its variants had previously received, under FDA 510(k) clearance (K131096), new and expanded claims and indications for use, as indicated below:

The Qoustic Wound Therapy System™ is indicated for producing and delivering low frequency ultrasound used to promote wound healing via:

  • Selective and non-selective dissection and fragmentation of soft and/or hard tissue
  • Surgical, excisional or sharp-edge wound debridement (acute and chronic wounds, burns) for the removal of nonviable tissue including but not limited to diseased tissue, necrotic tissue, slough and eschar, fibrin, tissue exudates, bacteria and other matter
  • Site cleansing irrigation and lavage of wound tissue (acute and chronic wounds, burns, diseased or necrotic tissue)
  • Contact and/or non-contact maintenance debridement for the removal of debris, exudates, fragments, bacteria, slough, fibrin, excised or fragmented tissue, and other matter
  • Preparing the wound bed for graft or other subsequent procedures using contact and/or non-contact techniques to achieve wound debridement

It is prescribed for patient population of any age with one or more wounds and/or that may also exhibit Diabetes Mellitus (DM)1

We are very excited at what this represents in the advancement of wound care, improved treatment methodologies and trajectories, and better patient compliance and outcomes.

Please call or contact us to find out how you can bring the Qoustic Wound Therapy System® to your facility and evaluate all of our flexible pricing options.


The Qoustic Wound Therapy System® is specifically designed to maintain sufficient momentum throughout the wound healing process for optimal healing. The Qoustic Wound Therapy System® is an ideal choice for treating a variety of wounds, including:

  • Pressure Ulcers
  • Arterial Wounds
  • Chronic Wounds
  • Diabetic Foot Ulcers
  • Osteomyelitis
  • Fistulas
  • Burns
  • Biofilm
  • Compromised Surgical Wounds
  • Venous Insufficiency Ulcers
  • Infected, Eczematous, Ulcerated or Devitalized Skin

The Qoustic Wound Therapy System® provides a superior debriding process for both treatment providers and patients. The unique domed shape of the Qoustic Qurette™ gives the treatment provider more control for gentle and selective volumetric removal of necrotic tissue. This state-of-the-art technology targets focused low frequency ultrasonic energy through saline to the wound bed. It is this unique delivery of low frequency ultrasonic energy that optimizes healing while potentially minimizing patient discomfort. Please contact us for more information.

Please call or contact us to find out how you can bring the Qoustic Wound Therapy System® to your facility and evaluate all of our flexible pricing options.


June 25, 2016
Health Canada issues Medical Device Licence to Arobella Medical, LLC.

May 16, 2014
Arobella Medical, LLC received new FDA 510(k) clearance (K131096) for the Qoustic Wound Therapy System™ platform.

November 6, 2013
Arobella showcases new ultrasound wound therapy hand piece at AMSUS 2013 Annual Meeting!

October 12, 2013
Arobella showcases new ultrasound wound therapy hand piece at 2013 Diabetic Limb Salvage!

May 3, 2013
Arobella introduces new ultrasound wound therapy hand piece at SAWC Spring 2013!

March 15, 2013
New ultrasound wound therapy hand piece launched!

February 25, 2013
Arobella Is Expanding! Looking For More Manufacturer Representatives - Sales

January 23, 2012
New ultrasound wound therapy arrives at Aurora Health – Fond du Lac

October 19, 2011
Arobella Medical Visited By Health & Medical Professionals From Iraq

August 26, 2011
Arobella Medical Announces Its Largest International Sale

July 7, 2010
Top Ten Innovations In Podiatric Care - Podiatry Today vol.23

January 4, 2010
Arobella Medical CEO Speaks at the 10th Annual Wound Healing: Science and Industry conference



The Effects of Low-frequency Ultrasound (35 kHz) on Methicillin-resistant Staphylococcus aureus (MRSA) in vitro

OWM article featuring Arobella Medical

Watch Videos

Qoustic Wound Therapy System Videos

View Slideshows

Wound Closure & Patient Treatment Slideshows


Join us at these shows:

Pacific Coast Region WOCN 2013 Conference

    February 28th - March 03rd
    Pasadena, CA

Diabetic Foot Global Conference (DFCon)

    March 21st - March 23rd
    Los Angeles, CA

American Podiatric Wound Care Association (APWCA) 2013 National Clinical Conference

    April 04th - April 07th
    Orlando, FL

The Symposium Advanced Wound Care - Spring (SAWC-Spring)

    May 01st - May 05th
    Denver, CO

All trademarks reserved by their respective holders and do not represent endorsement of this site, company, or its product.